Fluperlapin
Idi na navigaciju
Idi na pretragu
| |||
| (IUPAC) ime | |||
|---|---|---|---|
| 3-fluoro-6-(4-metilpiperazin-1-il)-11H-dibenzo[b,e]azepin | |||
| Klinički podaci | |||
| Identifikatori | |||
| CAS broj | 67121-76-0 | ||
| ATC kod | nije dodeljen | ||
| PubChem[1][2] | 49381 | ||
| ChemSpider[3] | 44882 | ||
| UNII | EWG253M961 
| ||
| ChEMBL[4] | CHEMBL63756
| ||
| Hemijski podaci | |||
| Formula | C19H20FN3 | ||
| Mol. masa | 309,381 g/mol | ||
| SMILES | eMolekuli & PubHem | ||
| |||
| Farmakoinformacioni podaci | |||
| Trudnoća | ? | ||
| Pravni status | |||
Fluperlapin (NB 106-689, fluoroperlapin) je triciklični atipični antipsihotik sa dodatnim antidepresivnim i sedativnim dejstvom. On je sintetisan 1979. Studiran je na životinjama i ljudima od 1984.[5] Mada je pokazao efikasnost u tretmanu mnoštva oboljenja, uključujući šizofreniju,[6][7][8][9] psihozu usled Parkinsonove bolest,[10] depresiju, i distoniju,[11] on nije plasiran na tržište.[5]
Reference[uredi - уреди | uredi kôd]
- ↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. http://www.sciencedirect.com/science/article/pii/S1359644610007737.
- ↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
- ↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. http://www.jcheminf.com/content/2/1/3.
- ↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594.
- ↑ 5,0 5,1 Ganellin, C. R.; Triggle, D. J.; Macdonald, F. (1997). Dictionary of pharmacological agents. CRC Press. str. 916. ISBN 978-0-412-46630-4. http://books.google.com/books?id=DeX7jgInYFMC&pg=PA916. Pristupljeno 15. 9. 2011.
- ↑ Fischer-Cornelssen, K. A. (1984). „Fluperlapine in 104 schizophrenic patients. Open multicenter trial”. Arzneimittel-Forschung 34 (1A): 125–130. PMID 6145428.
- ↑ Woggon, B.; Angst, J.; Bartels, M.; Heinrich, K.; Hippius, H.; Koukkou, M.; Krebs, E.; Küfferle, B. i dr.. (1984). „Antipsychotic efficacy of fluperlapine. An open multicenter trial”. Neuropsychobiology 11 (2): 116–120. PMID 6148712.
- ↑ Dieterle, D.; Eben, E.; Einhäupl, K.; Hippius, H.; Klein, H.; Rüther, E.; Schmauß, M. (2008). „The Effect of Fluperlapine in Acute Psychotic Patients”. Pharmacopsychiatry 17 (2): 57–60. DOI:10.1055/s-2007-1017408. PMID 6728910.
- ↑ Woggon, B.; Heinrich, K.; Küfferle, B.; Müller-Oerlinghausen, B.; Pöldinger, W.; Rüther, E.; Schied, H. W. (1984). „Results of a multicenter AMDP study with fluperlapine in schizophrenic patients”. Arzneimittel-Forschung 34 (1A): 122–124. PMID 6145427.
- ↑ Scholz, E.; Dichgans, J. (1985). „Treatment of drug-induced exogenous psychosis in parkinsonism with clozapine and fluperlapine”. European archives of psychiatry and neurological sciences 235 (1): 60–64. PMID 2864254.
- ↑ Pakkenberg, H.; Pedersen, B. (1985). „Medical treatment of dystonia”. Psychopharmacology. Supplementum 2: 111–117. ISSN 0179-8456. OCLC 10642795. PMID 2860654.
Literatura[uredi - уреди | uredi kôd]
- Ganellin, C. R.; Triggle, D. J.; Macdonald, F. (1997). Dictionary of pharmacological agents. CRC Press. str. 916. ISBN 978-0-412-46630-4. http://books.google.com/books?id=DeX7jgInYFMC&pg=PA916. Pristupljeno 15. 9. 2011.
Vidi još[uredi - уреди | uredi kôd]
Spoljašnje veze[uredi - уреди | uredi kôd]
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||